| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Health Care
| AbbVie is demonstrating a robust commitment to product development, evidenced by its strong pipeline that includes new treatments like upadacitinib and successful growth from offerings such as Rinvoq and Skyrizi. The company is experiencing increased demand in the immunology and neuroscience sectors, which is positively impacting its earnings. However, AbbVie faces significant product development hurdles, including a recently issued Complete Response Letter (CRL) from the FDA that poses challenges to its timelines. Balancing these positive developments with regulatory setbacks will be crucial for AbbVie's future performance. |
| The price action of ABBVIE INC (ABBV) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -0.1 is modestly bearish. The market sentiment at 0.6 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. There is no clear direction for ABBV since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.7, and the negative at -0.1 on 2026-04-29. The forces of Sector Price Trend (-0.9), and Stock Price Trend (-0.1) will drive down the price. The forces of Price Level Sentiment (0), Market Risk Appetite (0.1), Sentiment towards Fundamentals (1.2), Valuation Sentiment (1.5), and Option Sentiment (1.5) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| ABBV | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | 1%(0.1%) | 204.15 | 2.37% | 40 | 3.25% | -0.2% | -0.1 | 0.7 | 1.4% | 0.6 | Long | 55% | 1.2 | 6 |
| 2026-04-28 | 0%(0%) | 197.72 | 2.74% | 9 | 0.16% | -0.59% | -1.7 | -0.2 | 0.4% | 0.4 | Short | 55% | 0 | -1 |
| 2026-04-27 | 0%(0%) | 197.4 | 2.62% | 2 | -0.65% | -0.44% | -1.3 | -0.4 | 0.6% | 0.7 | Wait | 50% | -0.9 | -1 |
| 2026-04-26 | 0%(0%) | -1.7 | -0.4 | 0.2 | -1.2 | -1 | ||||||||
| 2026-04-25 | 0%(0%) | -1.7 | -0.4 | 0.2 | -1.5 | -1 | ||||||||
| 2026-04-24 | 0%(0%) | 198.69 | 2.34% | -0 | -1.15% | -0.49% | -1.7 | -0.1 | 0.7% | 0.4 | Short | 70% | -2 | -1 |
| 2026-04-23 | 0%(0%) | 201 | 2.07% | 4 | 0.25% | -0.53% | -1.4 | -0.1 | 0.9% | 0.6 | Wait | 50% | -1.5 | -7 |
| 2026-04-22 | 0%(0%) | 200.49 | 1.9% | -5 | -2.24% | -0.53% | -1.4 | -0.7 | 0.8% | 1.6 | Wait | 50% | 1.2 | -1 |
| 2026-04-21 | 0%(0%) | 205.09 | 1.66% | 20 | 0.7% | -0.1% | -0.6 | -0.2 | 0.9% | 1.1 | Short | 55% | 0.7 | -1 |
| 2026-04-20 | 0%(0%) | 203.67 | 1.67% | 9 | -2.26% | -0.14% | -0.4 | -0.7 | 1.1% | 1.2 | Short | 55% | 1.5 | -1 |
| Long is the preferred trading strategy with 55% chance of being right. Improving trend sentiment and positive hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| Analysis | ||
| ● AbbVie Inc. (ABBV) – Equity Research Report Sun. Mar 1, 2026 | ||
| 2026-04-29 17:02:54 Despite strong earnings, AbbVie faces ongoing cost pressures that have created concerns about future profitability amidst rising expenses. |
| 2026-04-29 17:02:54 AbbVie has raised its full-year financial guidance following a better-than-expected earnings report, reflecting confidence in growth. |
| 2026-04-29 17:02:54 The growth in sales of newer immunology drugs like Rinvoq and Skyrizi has been a significant contributor to AbbVie's recent earnings success. |
| 2026-04-29 17:02:54 AbbVie is in a critical transition phase as it moves away from the blockbuster drug Humira, focusing on new immunology drugs to drive growth. |
| 2026-04-29 17:02:54 AbbVie reported a strong first-quarter earnings performance with revenue and EPS beating estimates, indicating positive financial health. |
| 2026-04-29 15:48:39 AbbVie has raised its full-year EPS outlook, indicating confidence in its financial trajectory. |
| 2026-04-29 15:48:39 The decline in Humira sales reflects a significant shift in the market, affecting overall company performance. |
| 2026-04-29 15:48:39 The performance of Skyrizi and Rinvoq indicates a growing demand in the immunology and neuroscience sectors. |
| 2026-04-29 15:48:39 AbbVie's Q1 2026 earnings exceeded expectations, primarily driven by strong sales from Skyrizi and Rinvoq. |
| 2026-04-29 13:49:02 AbbVie's boost in outlook for 2026 indicates confidence in its future stock performance. |
| 2026-04-29 13:49:02 AbbVie reported better-than-expected earnings and revenue, leading to a rise in stock value. |
| 2026-04-29 11:50:16 The report includes an outlook boost for 2026, suggesting optimism for future growth. |
| 2026-04-29 11:50:16 Despite better-than-expected earnings, AbbVie's stock fell, highlighting a disconnect between earnings performance and market reaction. |
| 2026-04-29 11:50:16 The article discusses AbbVie's earnings report, which exceeded expectations, indicating strong financial performance. |
| 2026-04-29 09:36:21 AbbVie’s boosted outlook for 2026 signifies a positive long-term perception among analysts and investors. |
| 2026-04-29 09:36:21 The rise in AbbVie stock following earnings reports indicates a positive reaction from investors. |
| 2026-04-29 09:36:21 Increased sales from Botox and new immunology drugs suggest positive developments in product offerings. |
| 2026-04-29 09:36:21 The articles highlight AbbVie's improved earnings performance and raised profit forecasts, reflecting strong financial health. |